Halozyme

HALO

Market cap $7.82B

HALO's nearly 40% YTD surge is fueled by higher ENHANZE royalties. The Elektrofi deal also positions the company for long-term diversification.

Halozyme Therapeutics (HALO) stock could be a solid choice to leverage the current momentum. Why? Because it offers strong margins, a low-debt capital structure, reasonable valuation, and strong momentum.

HALO's impending acquisition of Elektrofi will add Hypercon tech to broaden its drug delivery platform and support long-term growth.

Halozyme Therapeutics, Inc. (NASDAQ:HALO ) M&A Call October 1, 2025 8:30 AM EDT Company Participants Tram Bui - Head of Investor Relations & Corporate Communications Helen Torley - President, CEO & Director Conference Call Participants Morgan Gryga - Morgan Stanley, Research Division Brendan Smith - TD Cowen, Research Division Michael DiFiore - Evercore ISI Institutional Equities, Research Division Corinne Jenkins - Goldman Sachs Group, Inc., Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Jason Butler - Citizens JMP Securities, LLC, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division David Risinger - Leerink Partners LLC, Research Division Presentation Operator Good morning. My name is Rob, and I will be your conference operator today.

Halozyme Therapeutics said on Wednesday it will buy privately held Elektrofi for $750 million in cash, to expand its lineup with a technology that can deliver biologic medicines in small, concentrated doses.

Royalty revenue contribution expected to begin as early as 2030 Initial partner targets include derisked MoAs that are approved blockbusters today Highly scalable licensing model and long duration IP into 2040s; potential for individual product IP extension through proprietary reformulation Two of Elektrofi's partners projected to begin Hypercon™ formulated product clinical development by year end 2026, or earlier Halozyme to host conference call and webcast today at 5:30am PT/ 8:30am ET SAN DIEGO , Oct. 1, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it has entered into a definitive agreement to acquire Elektrofi, Inc. ("Elektrofi"), a biopharmaceutical company with a breakthrough ultra-high concentration microparticle technology for biologics, branded Hypercon™. The transaction, which is comprised of an upfront payment of $750 million and up to three $50 million milestone payments contingent on three separate product regulatory approvals, was unanimously approved by the Boards of Directors of both Halozyme and Elektrofi.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Powell flags lofty valuations, but five high-earnings-yield stocks stand out as value picks in a cautious market.

The volatile biotech industry has done reasonably well so far in 2025 amid the ongoing tariff saga. Most pharma/biotech bigwigs are now investing heavily in manufacturing plants/operations in the United States as the Trump administration threatened of levying heavy tariffs on pharmaceutical imports (upto 250%) in a bid to boost domestic production.

Halozyme Therapeutics ( HALO ) is a $9 billion biotech focused on oncology and boasting sales and profit growth of 29% and 46%, respectively, while trading a sub-11x forward P/E. HALO is focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironments.